Status:
UNKNOWN
The Clopidogrel and Aspirin After Surgery for Coronary Artery Disease
Lead Sponsor:
China National Center for Cardiovascular Diseases
Conditions:
Atherosclerosis
Eligibility:
All Genders
18-80 years
Phase:
PHASE3
Brief Summary
Clopidogrel is a antiplatelet agent and is effective at reducing intimal hyperplasia in animal models of thrombosis.Several large clinical trials have demonstrated that clopidogrel with aspirin can re...
Eligibility Criteria
Inclusion
- Patients undergoing primary multi-vessel CABG with at least two saphenous vein grafts, with or without the use of cardiopulmonary bypass.
Exclusion
- Emergency surgery
- Valve surgery
- Redo CABG
- Left ventricle ejection fraction \< 30%
- Preoperative use of clopidogrel (with the exception of the current admission)
- Preoperative use of warfarin
- Allergy to aspirin or clopidogrel
- History of cerebrovascular accident
- History of severe liver disease
- Morbid obesity
- Current malignancy
Key Trial Info
Start Date :
December 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT00776477
Start Date
December 1 2007
Last Update
October 21 2008
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Institute of cardiovascular diseases,Fuwai hospital
Beijing, Beijing Municipality, China, 100037